Logo

Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Share this

M&A

Vertex to Acquire Semma Therapeutics for Developing Curative Cell-Based Therapies to Treat Type 1 Diabetes

Shots:

  • Vertex acquires Semma Therapeutics- in all cash transaction making a total deal value $950M and Semma will operate as a subsidiary of Vertex. The transaction is expected to be completed in Q4’19
  • The acquisition targets Semma’s unique investigational approach of combining the production of Islets of Langerhans cells in the pancreas with a delivery system to restore insulin secretion in T1D patients
  • Islet cell transplantation provides physiologic regulation of blood glucose- thus prevent both hyperglycemic and hypoglycemic episodes associated with the current SOC i.e- insulin injection & pumps

Click here to­ read full press release/ article

Ref: Vertex | Image: Vertex


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions